Dr. Ian Smith, is the founder and former Global Medical Director of Synexus (1998 – 2014). He was awarded an MBE for services to Health Research; for building a global clinical trials business called Synexus which was sold in 2016 for £178m. Dr. Smith was involved in the management buyout of Synexus in 2000, listing of Synexus onto the London Stock Exchange (AIM) and into all dealings with investors, before being sold to Lyceum Capital in 2007. Dr. Smith has completed more than 1000 clinical trials in the past 20 years in a wide variety of therapy areas.
A serial entrepreneur running biotech companies, who has brought over £8m of private investment (seed and Series A) from VCs & HNWs and grants into his business ventures. Dr. Khan has a PhD from Cambridge University in protein folding and molecular biology (2004) and is currently a Senior Research Associate in Biotechnology at Peterhouse College, The University of Cambridge. In 2009-10 he led his own research group at the Manchester Institute of Biotechnology, The University of Manchester in the development of novel molecular diagnostics and prior to this he worked at the Manchester Centre for Integrative Systems Biology. Dr. Khan has worked for GlaxoSmithKline in drug discovery, assay development and screening and obtained his PhD from Cambridge University in protein folding. Dr. Khan is also Chairman of Protein Technologies Ltd, a biotherapeutic CRO company based in Manchester. He is also a consultant and advisor of new biotechnologies to a number of large pharmaceutical companies and biotech investors.
Prof. Doig graduated in Chemistry from the University of Cambridge, where he stayed to complete his PhD on protein folding and peptide binding with Professor Dudley Williams, FRS, in 1991. He then carried out post-doctoral research in the Biochemistry Department at Stanford with Professor Robert Baldwin before joining UMIST in 1994. He is now a Professor of Biochemistry in the Faculty of Life Sciences at the University of Manchester. In addition to being an expert on Alzheimer’s disease and protein structure, Professor Doig was one of the founders of Senexis, a Cambridge based company focused on novel treatments for diseases resulting from the toxicity of amyloid-like proteins.
Prof. Herholz was a clinical specialist in neurology at municipal and university hospital, Cologne, Germany from 1982-90. Since 2005, after moving to the University of Manchester, he became professor in clinical neuroscience and head of the neuroscience imaging program at Wolfson Molecular Imaging Centre (WMIC). During this post, he became specialist in neuroimaging and clinical trials of AD. He was promoted to become the director of the Wolfson Molecular Imaging Centre (WMIC) from 2006-10.
Dr. Stanley is the inventor/co-inventor of >40 published patents in the fields of in vitro diagnostics, medical devices and drug discovery. He has developed assays to detect and quantity brain-derived oligomeric and aggregated protein biomarkers in the blood including beta amyloid and alpha synuclein. His current focus is on the diagnosis (and misdiagnosis) of Alzheimer’s Disease, Parkinson’s Disease and other Lewy Body disorders, such as Dementia with Lewy Bodies (DLB) and Multiple System Atrophy (MSA). Dr. Stanley is networked with a number of partners: The University of Liverpool, Lancaster University, Newcastle University and Microsens Biotechnologies and Cynapsedx.
Tony has deep business expertise gained in a variety of national and global roles during his career at AstraZeneca. As a Global Commercial Director he established a track record of exceeding targets and expectations. Under his commercial leadership AstraZeneca infection business increased from the 2003 annual turnover of $350m with a single brand, to the 2011 annual turnover of $1.9b multi-brand division with a healthy pipeline. As part of the management team tasked to transform their business unit performance Tony completed 5 in-licensing / acquisitions. He is effective at managing key strategic partner relationships, having taken responsibility for alliance management. Tony served for several years on the board of a subsidiary, AstraZeneca Ireland Operations, providing governance for investment decisions on projects and manufacturing facilities. In summary, Tony brings to PharmaKure areas of skill which include; new product development, brand launches, in-licensing and corporate acquisitions.
Ranked in the top 100 UK Scientists. Sir Alan Fersht’s current research at The University of Cambridge uses an amalgam of protein engineering, structural biology, biophysics and chemistry to study the structure, activity, stability and folding of proteins, and the role of protein misfolding and instability in cancer and disease. His group at the MRC Laboratory of Molecular Biology in Cambridge focuses on how mutation affects proteins in the cell cycle, particularly the tumor suppressor p53, in order to design novel anti-cancer drugs that function by restoring the activity of mutated proteins. Since October 2012-2018, he has been Master of Gonville and Caius College, Cambridge. Knighted in 2003 for his work on protein science, and has honorary degrees from Uppsala, Brussels, Weizmann Institute, Imperial College and The Hebrew University. He has honorary professorships in China in Shanghai, Chengdu and Qingdao. He has world-wide experience in the needs of science and biotechnology.
Dr. Well’s patent practice is principally in the pharmaceutical and chemical fields. He has extensive experience in securing patent protection for pharmaceuticals and specialises in drafting and prosecuting patent applications covering ‘repurposed drugs’, new chemical entities, salts, polymorphs, formulations (including advanced drug delivery technologies), manufacturing processes, medical uses, and medical devices.
Stuart is chairman of Panacea a regulatory affairs & pharmacovigilance company. The company can assist its clients to keep track of the ever-changing legislation in Europe, more specifically, providing support on the following regulatory activities: Marketing Authorisation applications and submissions Product information. Panacea holds an established approach to supporting companies, helping to effectively contribute new and improved products to the market in the most efficient manner, and with as little resources as allowable. Through offering their range of Clinical Trials Services, Panacea ensure all streamlined clinical trials meet the regulatory and ethical requirements.
Dr. Mucke is an accomplished scientist, science author, patent analyst and R&D manager who had a strong role in the repurposing of several drugs, including galantamine for Alzheimer’s disease. He also helped to take a pharmaceutical company public on the Frankfurt Stock Exchange in 1999. Dr. Mucke serves on several corporate scientific advisory boards and is an editorial board member and regular author of several scientific journals, such as the Pharmaceutical Patent Analyst. Among many other market and technology analyses, Dr. Mucke is the author of “Drug Repositioning: Extracting added value from prior R&D investments”, published by Insight Pharma Reports). He is founder of HM Pharma Consultancy, and undertakes corporate scientific & IP management of several pharma companies.